# BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

> **NCT06253195** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 33 (actual)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor
- Hormone-receptor-positive Breast Cancer
- Breast Cancer
- Metastatic Breast Cancer
- Hormone Receptor Positive Malignant Neoplasm of Breast
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** BGB-43395
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT06253195
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-10-26
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06253195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06253195, "BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06253195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*